指南与共识胸部肿瘤放疗姑息放疗与转移瘤

寡转移性非小细胞肺癌的治疗:ASTRO/ESTRO临床实践指南

Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline.
指南 / 共识 · Pract Radiat Oncol · 2023-04-25

美国放射肿瘤学会(ASTRO)与欧洲放射治疗与肿瘤学会(ESTRO)联合制定本指南,针对颅外寡转移性非小细胞肺癌(NSCLC)局部治疗的应用提出推荐。指南围绕5个关键问题,基于系统文献综述,强烈推荐以患者为中心的多学科决策,并对同步、异时、寡持续和寡进展等情形给出条件性推荐,涉及放疗、手术及系统治疗整合与放疗技术。

要点

  • 强烈推荐以患者为中心的多学科方法用于所有潜在治疗决策。
  • 根治性局部治疗仅当技术上可行且临床安全适用于所有病变部位(定义为5个或更少不同部位)时才相关。
  • 放疗和手术是唯一推荐用于寡转移性疾病患者管理的原发根治性局部治疗方式,并提供了选择指征。

核心结论

  • 目前关于局部治疗对寡转移性NSCLC总生存及其他生存结局的临床获益数据仍然稀少。
  • 随着支持局部治疗的数据快速涌现,本指南尝试根据现有数据质量,在多学科方法中结合患者目标与耐受性来构建推荐。

研究设计与样本

  • 由ASTRO和ESTRO联合召集工作组,基于系统文献综述,采用ASTRO指南方法学制定。
  • 工作组针对局部(放疗、手术、其他消融方法)和系统治疗在寡转移性NSCLC管理中的应用,聚焦5个关键问题。

主要发现

  • 基于缺乏显著的随机3期试验,强烈推荐以患者为中心的多学科方法用于所有潜在治疗决策。
  • 根治性局部治疗的整合仅当技术上可行且临床安全适用于所有病变部位(定义为5个或更少不同部位)时才相关。
  • 对颅外疾病的同步、异时、寡持续和寡进展情形,给出了根治性局部治疗的条件性推荐。
  • 放疗和手术是唯一推荐用于寡转移性疾病患者管理的原发根治性局部治疗方式,并提供了选择其中一种的指征。
  • 针对系统治疗与局部治疗的整合提供了序贯推荐,并对大分割放疗或立体定向体部放疗作为根治性局部治疗的最优技术使用(包括剂量和分割)提供了多条推荐。

关键数值与推荐

  • 强烈推荐:以患者为中心的多学科方法用于所有潜在治疗决策。
  • 条件性推荐:对颅外疾病的同步、异时、寡持续和寡进展情形给予根治性局部治疗。
  • 推荐:放疗和手术是唯一推荐用于寡转移性疾病患者管理的原发根治性局部治疗方式,并提供了选择指征。
  • 推荐:针对系统治疗与局部治疗整合的序贯推荐。
  • 推荐:对大分割放疗或立体定向体部放疗作为根治性局部治疗的最优技术使用(包括剂量和分割)的多条推荐。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 基于缺乏显著的随机3期试验,强烈推荐以患者为中心的多学科方法用于所有潜在治疗决策。
  • 目前关于局部治疗对寡转移性NSCLC总生存及其他生存结局的临床获益数据仍然稀少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This joint guideline by American Society for Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) was initiated to review evidence and provide recommendations regarding the use of local therapy in the management of extracranial oligometastatic non-small cell lung cancer (NSCLC). Local therapy is defined as the comprehensive treatment of all known cancer-primary tumor, regional nodal metastases, and metastases-with definitive intent. METHODS: ASTRO and ESTRO convened a task force to address 5 key questions focused on the use of local (radiation, surgery, other ablative methods) and systemic therapy in the management of oligometastatic NSCLC. The questions address clinical scenarios for using local therapy, sequencing and timing when integrating local with systemic therapies, radiation techniques critical for oligometastatic disease targeting and treatment delivery, and the role of local therapy for oligoprogression or recurrent disease. Recommendations were based on a systematic literature review and created using ASTRO guidelines methodology. RESULTS: Based on the lack of significant randomized phase 3 trials, a patient-centered, multidisciplinary approach was strongly recommended for all decision-making regarding potential treatment. Integration of definitive local therapy was only relevant if technically feasible and clinically safe to all disease sites, defined as 5 or fewer distinct sites. Conditional recommendations were given for definitive local therapies in synchronous, metachronous, oligopersistent, and oligoprogressive conditions for extracranial disease. Radiation and surgery were the only primary definitive local therapy modalities recommended for use in the management of patients with oligometastatic disease, with indications provided for choosing one over the other. Sequencing recommendations were provided for systemic and local therapy integration. Finally, multiple recommendations were provided for the optimal technical use of hypofractionated radiation or stereotactic body radiation therapy as definitive local therapy, including dose and fractionation. CONCLUSIONS: Presently, data regarding clinical benefits of local therapy on overall and other survival outcomes is still sparse for oligometastatic NSCLC. However, with rapidly evolving data being generated supporting local therapy in oligometastatic NSCLC, this guideline attempted to frame recommendations as a function of the quality of data available to make decisions in a multidisciplinary approach incorporating patient goals and tolerances.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Iyengar P, All S, Berry MF, et al. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline. Pract Radiat Oncol. 2023. PMID: 37294262. doi:10.1016/j.prro.2023.04.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。